Capricor Jumps 80.5% on Lancet-Backed Deramiocel Data as Cantor Lifts Target to $28
Updated
Updated · timothysykes.com · Aug 14
Capricor Jumps 80.5% on Lancet-Backed Deramiocel Data as Cantor Lifts Target to $28
2 articles · Updated · timothysykes.com · Aug 14
Summary
Capricor shares surged 80.52% after peer-reviewed Phase 3 HOPE-3 results in The Lancet strengthened confidence in deramiocel ahead of an Aug. 22 FDA decision.
HOPE-3 showed deramiocel slowed upper-limb decline by 54% and delivered cardiac benefits in Duchenne muscular dystrophy, giving outside validation to the data behind the active BLA review.
Cantor Fitzgerald upgraded the stock to Overweight and raised its price target to $28 from $3.50, while Oppenheimer kept an Outperform rating even after the stock’s roughly 70% slide.
The rally comes despite a recent 9-3 negative advisory committee vote and Capricor’s public dispute with FDA briefing analyses, which the company says relied on an outdated statistical plan.
Q2 brought no revenue and wider losses, but Capricor says cash and liquid resources can fund at least 12 months of operations, keeping investor focus on the binary FDA catalyst rather than financing risk.